首页|经导管主动脉瓣置换术围手术期共病诊治中国专家共识

经导管主动脉瓣置换术围手术期共病诊治中国专家共识

扫码查看
我国瓣膜病负担重,近十余年,经导管主动脉瓣置换术(TAVR)作为主动脉瓣狭窄重要的治疗方式目前已获得诸多研究证据支持.TAVR的适应证人群,绝大多数为老年、合并多种疾病、合并多种用药以及衰弱的群体,而合并疾病的种类和病情,TAVR围手术期合并疾病的管理与治疗,均直接影响了患者的预后,需给予足够的重视.为规范TAVR围手术期共病的诊治,瓣膜病共病诊治专家协作组讨论制定了 TAVR围手术期共病诊治中国专家共识,对衰弱、冠心病、神经系统并发症、肿瘤、非心脏外科手术需求、晚期肾病、严重肺功能障碍等七个共病的相关诊治情况统一意见.
Chinese experts'consensus on the comorbidity management in perioperative period of transcatheter aortic valve replacement
The burden of valve disease in our country is heavy.In the past decade,transcatheter aortic valve replacement(TAVR)has been an important treatment method for aortic valve stenosis and has received a lot of research evidence to support it.The indications for TAVR are mostly elderly people,those with multiple diseases and medications,and those who are frail.The types,conditions and management of comorbidities during perioperative period of TAVR surgery,directly affect the prognosis of patients.In order to standardize the management of comorbidities during the perioperative period of TAVR,a collaborative group of Chinese experts has discussed and formulated a consensus on the diagnosis and treatment of comorbidities during the perioperative period of TAVR.They have unified opinions on the treatment of seven comorbidities,including frailty,coronary heart disease,neurological diseases,tumors,non cardiac surgical needs,end-stage kidney disease,and severe pulmonary dysfunction.

Heart Valve DiseasesAortic ValvePerioperative periodComorbidity

瓣膜病共病诊治专家协作组、汪芳、吴永健

展开 >

北京医院心血管内科国家老年医学中心 中国医学科学院老年医学研究所,北京100730

阜外医院心内科 国家心血管病中心,北京 100037

心脏瓣膜疾病 主动脉瓣 围手术期 共病

国家重点研发计划资助中央高水平医院临床科研业务费

2020YFC2008100BJ-2022-117

2024

中华老年医学杂志
中华医学会

中华老年医学杂志

CSTPCD北大核心
影响因子:1.606
ISSN:0254-9026
年,卷(期):2024.43(10)